Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
This article was originally published in The Pink Sheet Daily
Executive Summary
Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.